Heron Therapeutics (HRTX)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Heron Therapeutics (HRTX)
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Key Insights
Critical company metrics and information
Share Price
$1.62Market Cap
$246.39 MillionTotal Outstanding Shares
152.10 Million SharesTotal Employees
126Dividend
No dividendIPO Date
August 27, 1987SIC Description
Pharmaceutical PreparationsHomepage
https://www.herontx.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Operating Activities, Continuing | $-8.29 Million |
Net Cash Flow, Continuing | $-9.12 Million |
Net Cash Flow | $-9.12 Million |
Net Cash Flow From Investing Activities | $-1.54 Million |
Net Cash Flow From Investing Activities, Continuing | $-1.54 Million |
Net Cash Flow From Financing Activities | $716000.00 |
Net Cash Flow From Financing Activities, Continuing | $716000.00 |
Net Cash Flow From Operating Activities | $-8.29 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Diluted Average Shares | $156.60 Million |
Operating Expenses | $125.35 Million |
Income/Loss From Continuing Operations Before Tax | $12.38 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-27.97 Million |
Revenues | $137.74 Million |
Income/Loss From Continuing Operations After Tax | $-27.97 Million |
Net Income/Loss | $-27.97 Million |
Basic Average Shares | $156.60 Million |
Benefits Costs and Expenses | $125.35 Million |
Net Income/Loss Attributable To Parent | $-27.97 Million |
Operating Income/Loss | $-25.92 Million |
Cost Of Revenue | $38.30 Million |
Research and Development | $38.07 Million |
Basic Earnings Per Share | $0.16 |
Gross Profit | $99.43 Million |
Costs And Expenses | $125.35 Million |
Other Operating Expenses | $87.28 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Diluted Earnings Per Share | $0.16 |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Equity Attributable To Noncontrolling Interest | $0.00 |
Current Assets | $195.19 Million |
Equity Attributable To Parent | $-40.01 Million |
Equity | $-40.01 Million |
Other Current Liabilities | $66.83 Million |
Other Non-current Assets | $10.18 Million |
Noncurrent Liabilities | $175.24 Million |
Wages | $8.53 Million |
Noncurrent Assets | $25.59 Million |
Other Current Assets | $78.34 Million |
Cash | $70.90 Million |
Fixed Assets | $15.41 Million |
Inventory | $45.95 Million |
Accounts Payable | $10.19 Million |
Liabilities | $260.78 Million |
Assets | $220.78 Million |
Liabilities And Equity | $220.78 Million |
Current Liabilities | $85.54 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
â“’ 2024 Financhle. All Rights Reserved.